Transcutaneous Tibial Nerve Stimulation for Spinal Cord Injury Neurogenic Bladder
Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER, HOUSTON · Apr 14, 2020
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating whether a treatment called transcutaneous tibial nerve stimulation (TTNS) can help improve bladder function in people who have recently experienced a spinal cord injury. TTNS involves using gentle electrical stimulation on the leg to see if it can lead to better bladder control for patients with spinal cord injuries, particularly those with higher-level injuries (at or above the T9 level).
To participate in this study, individuals need to be between 18 and 75 years old and have been admitted to a rehabilitation facility within six weeks of their injury. They should be able to speak English or Spanish and live near the study location for follow-up visits. However, those with certain medical histories, such as specific bladder or nerve conditions, or those who are pregnant, will not be eligible to join. Participants can expect to receive the TTNS treatment and will be monitored to evaluate its effects on their bladder outcomes, helping researchers learn if this could be a helpful therapy for others in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18-75 years old
- • Traumatic or non-traumatic SCI
- • Admitted to inpatient rehabilitation within 6 weeks
- • T9 level of injury and above who are at greatest risk of morbid NGB
- • Regionally located to allow follow-up
- • English or Spanish speaking
- Exclusion Criteria:
- • History of genitourinary diagnoses (i.e. prostate hypertrophy, overactive bladder, cancer, etc.)
- • History of central nervous system disorder (i.e. prior SCI, stroke, brain injury, Parkinson's disease, MS, etc.)
- • History of peripheral neuropathy
- • pre-SCI symptoms of peripheral neuropathy (numbness and/or tingling in feet, sharp/jabbing/burning pain in feet, sensitivity to touch, lack of coordination, muscle weakness, etc.)
- • Pregnancy
- • Known injury to the lumbosacral spinal cord or plexus, or pelvis with associated neuropathy
- • concern for tibial nerve pathway injury
- • absence of toe flexion or autonomic dysreflexia during electric stimulation test
- • Potential for progressive SCI including neurodegenerative SCI, ALS, cancer myelopathy, Multiple sclerosis, transverse myelitis
About The University Of Texas Health Science Center, Houston
The University of Texas Health Science Center at Houston (UTHealth) is a leading academic institution dedicated to advancing health through education, research, and clinical practice. As a prominent sponsor of clinical trials, UTHealth leverages its extensive resources and expertise in biomedical research to facilitate innovative studies aimed at improving patient outcomes. The institution is committed to fostering a collaborative environment that promotes scientific discovery and the translation of research findings into effective healthcare solutions, all while adhering to the highest ethical standards and regulatory guidelines. With a multidisciplinary approach, UTHealth plays a critical role in addressing complex health challenges and enhancing the quality of life in diverse communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Washington, District Of Columbia, United States
Houston, Texas, United States
Patients applied
Trial Officials
Argyrios Stampas, MD
Principal Investigator
UTHealth and TIRR Mermorial Hermann
Suzanne Groah, MD
Principal Investigator
MedStar National Rehabilitation Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials